Opinion

Video

Data in Resected Colorectal Cancer Liver Metastases

Author(s):

Ryan Merkow, MD, MSLouise Catherine Connell, MB BCh BAO, BMedSc

Louise Catherine Connell, MB BCh BAO, BMedSc, and Ryan Merkow, MD, MS, review clinical trial data on resected colorectal cancer liver metastases.

Related Videos
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Related Content
Carlyn Rose Tan, MD
June 5th 2024

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center
June 3rd 2024

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center
May 2nd 2024

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

Arndt Vogel, MD
June 2nd 2024

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center
June 2nd 2024

Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer